Resolving a long-standing dispute, San Diego’s Gen-Probe (NASDAQ: [[ticker:GPRO]]) agreed to invest $5 million in its Canadian partner and to begin clinical trials of its prostate cancer test later this year. The deal gives Gen-Probe a 10 percent stake in Toronto-based DiagnoCure and revises the timeline for developing the test, which had become a sticking … Continue reading “Gen-Probe Amends Deal to Get Promising Test for Prostate Cancer”
Author: Denise Gellene
Ardea Biosciences Finds Early Results of Drug Candidate Equivalent to Existing Gout Treatment
San Diego’s Ardea Biosciences (NASDAQ: [[ticker:RDEA]]) said today its experimental gout drug performed no better than existing drugs in an early stage study, but CEO Barry Quart nevertheless said he’s happy with the result. “This is the first stage of drug development and we have not yet optimized the dose,” Quart said. “We have demonstrated … Continue reading “Ardea Biosciences Finds Early Results of Drug Candidate Equivalent to Existing Gout Treatment”